ZIOP - ZIOPHARM Oncology, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

ZIOPHARM Oncology, Inc.

Parris Building 34
Navy Yard Plaza
Boston, MA 02129
United States
617-259-1970
http://www.ziopharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees36

Key Executives

NameTitlePayExercisedAge
Dr. Laurence James Neil Cooper Ph.D., M.D.Chief Exec. OfficerN/AN/A52
Mr. Kevin G. LafondSr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. ControllerN/AN/A61
Mr. Caesar J. BelbelExec. VP, Chief Legal Officer & Sec.640.21k1.62M57
Dr. Francois Lebel M.D.Chief Medical Officer and Exec. VP of R&DN/AN/A65
Dr. David M. Mauney M.D.Exec. VP, Chief Bus. Officer & Interim COON/AN/A48
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Corporate Governance

ZIOPHARM Oncology, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 4. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.